BME Launches New Speed™ Continuous Active Compression System

SAN ANTONIO, Sept. 3, 2013 /PRNewswire/ -- BME, Inc. (BioMedical Enterprises, Inc., www.bme-tx.com), the privately held U.S. Leader in Nitinol Technology Implants and Instruments known under the brands of: Speed™ (fully-disposable continuous active compression system), HammerLock^®  (intramedullary hammertoe correction system), OSStaple™ (Nitinol continuous active compression system) and OSSforce™ (heat-activating implant controller), has announced today its' introduction of a new, improved Speed™ Continuous Active Compression System.

Unique to BME, the new Speed Zero-Torque™ Insertion Tool no longer requires a surgeon to "twist off" the implant from the insertion tool during implantation.  Rather, the surgeon merely depresses the button release key on the insertion tool for zero degrees of resistance, easy and immediate implantation offering the surgeon consistent, reproducible results in the operating room suite.

Keith M. Peeples, President & CEO of BME, shared his determination and focus on continuous improvement of the BME brands.  In particular, Mr. Peeples spoke about their latest innovation.  "The new proprietary Speed instrumentation system was designed by Foot & Ankle specialists for Foot & Ankle surgeons.  It is the latest example of our commitment to advancing our Nitinol technologies for optimized patient outcomes.  Specifically, the new patent-pending Speed Zero-Torque Insertion Tool will dramatically improve the insertion of BME Nitinol implants."

In addition, BME has also advanced the design of the Speed Drill Guide and Drill Guide Handle within the fully disposable Speed™ Instrumentation System.  These instrument improvements will optimize purchase on the bone while drilling and accommodate virtually all types of surgeon use and techniques.

About BME, Inc.

BME, Inc. is the only U.S. manufacturer of Nitinol metal implants for musculoskeletal and soft tissue fixation.  For over a decade, BME has spearheaded the innovation of the Nitinol technologies in the U.S. market, and continues the advancement of Nitinol implants and instruments.  This is accomplished by BME developing new standards for manufacturing processes, defining new clinical parameters for product development, adding to its surgeon advisory boards, and focusing on the education of our surgeon communities on the clinical benefits of the Nitinol technology.  Innovation and strategic partnerships will further define the role of BME as leaders as demonstrated in our commitment to the BME surgeon and his patients.

SOURCE BioMedical Enterprises, Inc.